Browsing by Author "Colombato, Luis"

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    A Latin American survey on demographic aspects of hospitalized, decompensated cirrhotic patients and the resources for their management
    (2020) Vorobioff, Julio D.; Contreras, Fernando; Tanno, Federico; Hernandez, Lucia; Bessone, Fernando; Colombato, Luis; Adi, Jose; Fassio, Eduardo; Felgueres, Mirta; Fernandez, Guillermo; Gaite, Luis; Gibelli, Diana; Gomez Darrichon, Hernan; Lafage, Matias; Lombardo, Daniel; Lopez, Susana; Mateo, Alejandro; Mendizabal, Manuel; Pecoraro, Julieta; Ruf, Andres; Ruiz, Pablo; Severini, Javier; Stieben, Teodoro; Sixto, Marcela; Zarate, Fabian; de la Barra Barraza, Sergio; Donoso Sierra, Irene; Rivas Pacheco, Violeta; Roblero, Juan P.; Rojas, Juan O.; Ruiz Gonzalez, Patricio; San Martin Rodriguez, Diego; Sierralta, Armando; Urzua Manchego, Alvaro; Valdes, Eliana; Yaquich, Pamela; Wolff, Rodrigo; Beltran Valdivia, Flor; Gallegos, Roxana C.; Galloso, Rocio; Marcelo, Julio S.; Montes, Pedro; Tenorio, Laura; Veramendi, Isabel; Alava, Elizabeth; Armijos, Ximena; Benalcazar, Gonzalo; Carrera, Enrique; Pazmino, Galo F.; Marriott Diaz, Eduardo; Garassini, Miguel; Marrero, Rosalia P.; Infante, Mirta; Paez Suarez, Dayron; Gutierrez, Jose C.; Villadoniga Reyes, Carmen M.; Serrano, Yoel M.; Hernandez Hernandez, Rivardo; Martinez Martinez, Orelvis; Perez Gonzalez, Teresita; Andara, Maria T.; Sanchez Hernandez, Marco; Gerona, Solange; Garcia, Ivan; de la Tijera, Fatima; Pessoa Lopez, Edmundo; Torres, Kenia; Garzon, Martin
    Introduction & objectives: Liver cirrhosis is a major cause of mortality worldwide. Adequate diagnosis and treatment of decompensating events requires of both medical skills and updated technical resources. The objectives of this study were to search the demographic profile of hospitalized cirrhotic patients in a group of Latin American hospitals and the availability of expertise/facilities for the diagnosis and therapy of decompensation episodes.
  • No Thumbnail Available
    Item
    Serious liver injury induced by Nimesulide: an international collaborative study
    (2021) Bessone, Fernando; Hernandez, Nelia; Mendizabal, Manuel; Ridruejo, Ezequiel; Gualano, Gisela; Fassio, Eduardo; Peralta, Mirta; Fainboim, Hugo; Anders, Margarita; Tanno, Hugo; Tanno, Federico; Parana, Raymundo; Medina-Caliz, Inmaculada; Robles-Diaz, Mercedes; Alvarez-Alvarez, Ismael; Niu, Hao; Stephens, Camilla; Colombato, Luis; Arrese, Marco; Reggiardo, M. Virginia; Ono, Suzane Kioko; Carrilho, Flair; Lucena, M. Isabel; Andrade, Raul J.
    Nimesulide is a non-steroidal anti-inflammatory drug still marketed in many countries. We aim to analyze the clinical phenotype, outcome, and histological features of nimesulide-induced liver injury (nimesulide-DILI). We analyzed 57 cases recruited from the Spanish and Latin American DILI registries. Causality was assessed by the RUCAM scale. Mean age of the whole case series was 59 years (86% women) with a median time to onset of 40 days. A total of 46 patients (81%) were jaundiced. Nimesulide-DILI pattern was hepatocellular in 38 (67%), mixed in 12 (21%), and cholestatic in 7 (12%) cases. Transaminases were elevated with a mean of nearly 20-fold the upper limit of normality (ULN), while alkaline phosphatase showed a twofold mean elevation above ULN. Total bilirubin showed a mean elevation of 13-fold the ULN. Liver histology was obtained in 14 cases (25%), most of them with a hepatocellular pattern. Median time to recovery was 60 days. Overall, 12 patients (21%) developed acute liver failure (ALF), five (8.8%) died, three underwent liver transplantation (5.3%), and the remaining four resolved. Latency was <= 15 days in 12 patients (21%) and one patient developed ALF within 7 days from treatment initiation. Increased total bilirubin and aspartate transaminase levels were independently associated with the development of ALF. In summary, nimesulide-DILI affects mainly women and presents typically with a hepatocellular pattern. It is associated with ALF and death in a high proportion of patients. Shorter (<= 15 days) duration of therapy does not prevent serious nimesulide hepatotoxicity, making its risk/benefit ratio clearly unfavorable.